Slide 1: Investor Presentation August 2020
For personal use only Investor Presentation August 2020 P H I L I P D AF F AS , C E O & M D P AI N C H E K L T D | AS X :P C K 1 |
Slide 2: Executive Summary
EXECUTIVE SUMMARY For personal use only Software-As-A- Clinically & Large global markets – now Better outcomes for Service that utilizes commercially validated in global commercialization patients & enterprise AI for the detection of with key regulatory phase based on strong customers pain via video
Slide 3: The Problem
THE PROBLEM For personal use only Pain assessment is difficult especially for those who This can lead to adverse cannot communicate such impact on quality of care, as people living with operational efficiency & dementia or compliance infants/toddlers Pain is often under detected, leading to under tr
Slide 4: PainChek gives a voice to people who cannot verbalise pain
For personal use only PainChek® gives a voice to people who cannot reliably verbalise their pain 4 |
Slide 5: Pain Assessment Is Ready for Disruption
PAIN ASSESSMENT IS READY FOR DISRUPTION For personal use only PainChek® builds on the benefits of the Abbey Pain Scale1, maintaining clinical practice while improving Abbey Pain Scale PainChek® clinical process & brings it into the digital age by: Using video/AI to automate the facial expression ass
Slide 6: Australian Federal Government Support
AUSTRALIAN FEDERAL GOVERNMENT SUPPORT $5M – EXTENDED TO JUNE 2021 For personal use only Australian Govt has pledged $5m to implement PainChek into the residential aged care (RAC) market Govt paying for a 12-month PainChek license subscription for up to 100,000 beds Govt wants to aid rapid adoption o
Slide 7: PainChek Protecting the Vulnerable During COVID-19
PAINCHEK® — PROTECTING THE VULNERABLE DURING COVID-19 For personal use only PainChek can be implemented remotely • PainChek® harnesses online communication channels, such as video conferencing, webinars, and email, to roll-out with no need for our team to physically access aged care facilities. • Pa
Slide 8: June 2020 Quarterly Update
JUNE 2020 QUARTERLY UPDATE For personal use only Total beds under license equate to $2.66m in normalized contracted ARR in year 2 of client contracts (post Govt initiative) Company continuing to target 100,000 dementia bed’s under license by Q2 2021 PainChek continued to deliver strong sales growth
Slide 9: Contracted Approved Beds
CONTRACTED APPROVED BEDS 160,000 contracted approved beds places would equate to $7M+ ARR1 For personal use only Post-govt grant Post-govt grant Pre-govt grant Pre-govt grant Total approved beds contracted in all markets as well as the dementia 1Contracted ARR for quarters to 30 Sept 2019 were a mul
Slide 10: PainChek Remote Digital Capability
PAINCHEK® REMOTE DIGITAL CAPABILITY For personal use only 192 Providers managing 612 facilities have been given “With the advent of COVID-19, IRT Group rapidly changed its rollout access to PainChek & training approach to PainChek, adopting a remote training approach & running in excess of 72 video
Slide 11: App Utility Rapid Growth During COVID-19
APP UTILITY RAPID GROWTH DURING COVID -19 For personal use only Monthly number of pain Cumulative Number of PainChek assessments continues to rise Assessments (from 1 Jan 2018) 50,000 + pain assessment increase from April to July 2020 160,000 151,731 Monthly assessments per dementia 140,000 resident
Slide 12: Targeting 100,000 Govt Funded Dementia Beds
TARGETING 100,000 GOVT FUNDED DEMENTIA BEDS (160,000 Approved Beds1) by June 2021 For personal use only Intra-govt grant Intra-govt grant Pre-govt grant Pre-govt grant Total number of contracted clients & RACs across all of PainChek’s target markets Total approved beds contracted in all markets & th
Slide 13: Implemented Beds
IMPLEMENTED BEDS Improvements to online training have seen an 80% increase in implemented beds during the June quarter For personal use only Intra - COVID 19 Pre-COVID 19 A lag exists in implementing the total number of contracted beds due to ability to schedule implementation across multiple sites,
Slide 14: Diversified Customers & Partners
DIVERSIFIED CUSTOMERS & PARTNERS For personal use only Example Aged Care Customers Advocates 14 |
Slide 15: Large Market Opportunity
LARGE MARKET OPPORTUNITY For personal use only ENTERPRISE DEMENTIA MARKET VALUE Aus UK US ROW est TOTAL No. Aged Care Beds 0.22m 0.54m 1.7m 4.5m 6.96m Annual Market Value @ A$11m A$26m A$81m A$216m A$334m A$4 per bed per month CONSUMER DEMENTIA MARKET VALUE Aus EU US ROW est TOTAL No. of People livi
Slide 16: Australian Home Care Market
AUSTRALIAN HOME CARE MARKET PainChek Home Care market opportunity For personal use only • Pilot programs negotiations in process with Healthcare Australia & NovaCare • $2Bn Federal Funding with $0.5Bn of new packages to meet need • 129,000 consumers with existing Home Care Packages (HCP) • Market en
Slide 17: PainChek in North America
PAINCHEK IN NORTH AMERICA For personal use only PCK Submission in place Canadian market PCK in active negotiation to Early entry to Canada will with Canada Health to opportunity is significant extend Australian establish a North American enter Canadian market as 250,000 aged care beds business agree
Slide 18: Collaboration & Hospital Market Opportunity
COLLABORATION & HOSPITAL MARKET OPPORTUNITY For personal use only 25-42% of all hospital beds occupied by people living with dementia Successful completion of the HealthWorks programme in December 2019 – technology integration opportunities ongoing Philips & PainChek collaborative clinical study ANN
Slide 19: New Product Development: Pre-Verbal Children's App
NEW PRODUCT DEVELOPMENT: PRE-VERBAL CHILDREN’S APP For personal use only Parents/practitioners have difficulty discerning APP SCREENSHOT CONSUMER PRE-VERBAL CHILDREN TARGET MARKET VALUE whether pre-verbal children (0-3 years) are in genuine pain or Childrens Hospitals just crying from discomfort, hu
Slide 20: New Product Launches
NEW PRODUCT LAUNCHES For personal use only Initial market entry with Direct to Carer 47 Million people living Product Significant market Enterprise versions to market expansion with dementia at home development to expansion potential into validate utility with Health when HCP support worldwide – 400
Slide 21: Highlights of PainChek
HIGHLIGHTS OF PAINCHEK® For personal use only Initial enterprise B2B Embedded nature of Low operating Low customer model small sales PainChek® technology costs; significant acquisition cost for force requirement operating leverage consumer model • Requires small global sales • Minimal churn to date
Slide 22: Catalysts & Expected Newsflow
CATALYSTS & EXPECTED NEWSFLOW For personal use only 1. Launch Home Care dementia 2. Canadian regulatory 3. TGA & CE Mark 4. FDA de Novo product in Australia – Q4 clearance Q4 2020 submission for pre-verbal clearance submitted 2020, Europe – CY 2021 & market entry Q1 2021 children product – CY for US
Slide 23: The Team
THE TEAM For personal use only Philip Daffas Prof. Jeff Hughes Andrew Hogan CEO & Managing Chief Scientific Manager, National Director, MBA, BSc Officer PhD, MPS Rollout Philip is a highly accomplished global business Jeff is a professor in the School of Pharmacy, Andy is a Psychologist, management
Slide 24: The Board
THE BOARD For personal use only John Murray Chairman John Murray Philip Daffas Ross Harricks Adam Davey Non- Exec Chair CEO & Managing Director Non-Exec Director Non-Exec Director 25 years in tech & Venture Philip is a highly accomplished Senior global medical device Corporate finance executive Capi
Slide 25: Corporate Summary
CORPORATE SUMMARY For personal use only PainChek Ltd (ASX:PCK) Financial information Share price (A$) Volume (m) Share price (1st August 2020) A$0.12 0.40 50.00mm Shares on issue 1,035.5m 0.35 40.00mm Market capitalisation A$124m 0.30 Cash (30 June 2020) A$6.1m 0.25 30.00mm 0.20 Debt Nil 0.15 20.00m
Slide 26: www.painchek.com
For personal use only www.painchek.com 26 |